BioArctic Neuroscience (Sweden)

Recent papers from BioArctic Neuroscience (Sweden)

1. Endogenously generated Dutch‐type Aβ non‐fibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammationAlzheimer s & Dementia · 2026
2. Lecanemab promotes Fc receptor-dependent cell-mediated internalization and degradation of aggregated amyloid-beta in vitro and ex vivoNeuroscience Letters · 2026
3. The Uppsala APP Mutation Promotes Wild‐Type Amyloid‐β Aggregation and Deposition In VivoAdvanced Science · 2026
4. Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathiesNeurotherapeutics · 2025
5. High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer doseFluids and Barriers of the CNS · 2025
6. Fluorine-18 ImmunoPET Imaging of Antibody Brain Kinetics and Amyloid-Beta PathologyACS Pharmacology & Translational Science · 2025
7. The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivoFluids and Barriers of the CNS · 2025
8. Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model miceNature Aging · 2025
9. Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseThe Journal of Prevention of Alzheimer s Disease · 2025
10. A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathologyNeurotherapeutics · 2024
11. MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non‐clinical species and Alzheimer's disease patientsAlzheimer s & Dementia · 2024
12. Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese AdultsThe Journal of Clinical Pharmacology · 2024
13. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brainsMolecular and Cellular Neuroscience · 2024
14. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic miceMolecular and Cellular Neuroscience · 2024
15. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalitiesScientific Reports · 2024
16. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibodymAbs · 2024
17. Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletionActa Neuropathologica Communications · 2024
18. SARM1 is responsible for calpain-dependent dendrite degeneration in mouse hippocampal neuronsJournal of Biological Chemistry · 2024
19. A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s diseaseUpsala Journal of Medical Sciences · 2023
20. Comparing in vitro affinity measurements of antibodies to TfR1: Surface plasmon resonance versus on-cell affinityAnalytical Biochemistry · 2023